Skip to product information
1 of 1

GeneBio Systems

Recombinant Mouse IGFBP6/IBP-6 Protein (His Tag)

Recombinant Mouse IGFBP6/IBP-6 Protein (His Tag)

SKU:PKSM040673

Regular price ¥174,600 JPY
Regular price Sale price ¥174,600 JPY
Sale Sold out
Shipping calculated at checkout.

Size: 100μg

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: IGFBP-6

Research Areas:

Conjugation:

Target Species: Mouse

Expression Host: HEK293 Cells

Application: Cell culture

Fusion tag: C-His

UNIProt ID: P47880

Accession: NP_032370.2

Background: Insulin-like growth factor binding protein 6 (IGFBP6) is a 24-kDa protein that binds insulin-like growth factor 1 (IGF-1) and IGF-2 with high affinity and inhibits IGF action in vitro. The Insulin-like growth factor-binding protein also known as IGFBP serves as a carrier protein for Insulin-like growth factor 1. IGFBPs are clearly distinct but are sharing regions with strong homology. All members of the IGFBP family bind IGF-I and IGF-II with about equal affinity. Insulin-like growth factor (IGF) binding proteins (IGFBPs) have been shown to either inhibit or enhance the action of IGF, or act in an IGF-independent manner in the prostate. IGF-binding protein-4 (IGFBP-4) inhibits IGF-I action in vitro and is the most abundant IGFBP in the rodent arterial wall. IGFBP6 is directly downregulated by the beta-catenin/TCF complex in desmoid tumors, and imply a role for the IGF axis in the proliferation of desmoid tumors. There is mounting evidence that the structure of the IGFBP proteins plays a key role in the regulation of IGF bioavailability, by modulating its molecular size, capillary membrane permeability, target tissue specificity, cell membrane adherence and IGF affinity.

Concentration:

Activity: Measured by its ability to inhibit the biological activity of IGFII on MCF7 human breast adenocarcinoma cells. The ED50 for this effect is typically 1-4 μg/ml in the presence of 20 ng/mL mouse IGFII.

Sequence: Met 1-Gly 238

Purity: > 92 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 24 kDa

ObservedMW: 30 kDa

View full details